Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 2:56 AM
Ignite Modification Date:
2025-12-25 @ 2:56 AM
NCT ID:
NCT00143533
Brief Summary:
The primary purpose of this study is to estimate the maximum tolerated dose of irinotecan with the use of cefpodoxime for pediatric solid tumor patients.
Detailed Description:
This is a phase I study with the exploratory investigation of at least four dosage levels (20, 30, 45, 60) to define the tolerable dose for phase II studies. Primary consideration will be given to determinations of the qualitative and quantitative toxicity of the administration of irinotecan with cefpodoxime, and pharmacokinetics of irinotecan when given with cefpodoxime.
Standard phase I escalation study in cohorts of 3-6 patients. Starting level is 20 mg/m2/d, and subsequent levels will be 30 mg/m2/d, 45 mg/m2/d and 60 mg/m2/d. An amendment to the study has included an intermediate level at 40 mg/m2/d.
Irinotecan will be administered as a 60-minute intravenous infusion daily for 5 consecutive days, followed by a 2 day rest, and followed by an additional 5 consecutive days course \[(qd x 5) x 2\]. Twenty-one days from the first dose will be considered one cycle of therapy. Cefpodoxime will be given orally at 10 mg/kg/day divided BID, starting 2 days prior to the beginning of the first course of irinotecan, and will be continued for the duration of study participation.
Additional objectives include:
* To describe the pharmacokinetics of intravenous irinotecan when given with oral cefpodoxime.
* To describe the dose-limiting toxicity/ies of irinotecan given on the \[(qd x 5) x 2\] with oral cefpodoxime.
* To evaluate the effect of the administration of oral cefpodoxime on the amount of intestinal beta-glucuronidase.
* To correlate the incidence and severity of diarrhea with the amount of intestinal beta-glucuronidase.
* To describe the toxicities of irinotecan given at doses above 20 mg/m2/d
* To note tumor responses within the confines of a phase I trial
Study:
NCT00143533
Study Brief:
Protocol Section:
NCT00143533